Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial

Overview

About this study

The purpose of this study is to assess the impact of olpasiran on major cardiovascular events in patients with atherosclerotic cardiovascular disease (ASCVD) and elevated lipoprotein (a) (Lp[a]) ≥ 200 nmol/L. The primary objective is to compare the effect of treatment with olpasiran, to placebo, on the risk for coronary heart disease death, myocardial infarction, or urgent coronary revascularization in these patients.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

- Age 18 to ≤ 85 years

- Lp(a)≥ 200 nmol/L during screening

- History of ASCVD as evidenced by history of either:

- Myocardial infarction (presumed type 1 event due to plaque rupture/erosion) and/or

- Coronary revascularization with percutaneous coronary intervention AND at least 1 additional risk factor.

Exclusion Criteria:

- Severe renal dysfunction

- Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 x upper limit of normal (ULN), or total bilirubin (TBL) > 2 x ULN during screening

- History of hemorrhagic stroke

- History of major bleeding disorder

- Planned cardiac surgery or arterial revascularization

- Severe heart failure

- Current, recent, or planned lipoprotein apheresis

- Previously received ribonucleic acid therapy specifically targeting Lp(a)

Eligibility last updated 8/8/23. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Iftikhar Kullo, M.D.

Closed for enrollment

Contact information:

Preventive Heart Research Team

(507) 538-7425

RSTCRVRUPREVENT@mayo.edu

More information

Publications

Publications are currently not available
.
CLS-20544528

Mayo Clinic Footer